但目前SURPASS试验主要招募的是白色人种患者,缺乏关于中国患者的数据,这是一个重要的缺口,因为中国是糖尿病患者人数最多的国家,占全球糖尿病患者总数的四分之一以上。 为进一步证明替西帕肽在亚洲患者群体中的有效性和安全性,研究团队开展了一项随机、开放标签的3期试验(SURPASS-AP-Combo),在中国、韩国、澳大利亚和印...
在SURPASS-AP-Combo试验的事后亚组分析中,研究人员探讨了不同基线特征的2型糖尿病(T2D)患者对替泽帕肽反应的差异。这项分析考察了年龄、性别、基线HbA1c、体重指数(BMI)、体重、糖尿病病程及口服降糖药使用情况如何影响患者对替泽帕肽的反应。 研究结果表明,在第40周时,不论替泽帕肽的剂量如何,所有治疗组的HbA1c...
Methods This was a post hoc analysis of the SURPASS AP-Combo study. Baseline characteristics, changes in metabolic markers, and safety were compared between tirzepatide-treated patients achieving HbA1c<7.0% (<53mmol/mol) and those achieving ≥7.0% (≥53mmol/mol) at week 40. Among patients ...
et al. Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nat Med 29, 1500–1510 (2023). https://doi.org/10.1038/s41591-023-02344-1 Download citation Received10 November 2022 Accepted07 ...
SURPASS-AP-Combo 研究以中国人群为主,Tirzepatide 较甘精胰岛素组的 HbA1c及体重降低更显著,为国内 T2DM 患者治疗带来坚实的证据支持。 SURPASS 1～5 系列研究涵盖糖尿病疾病进展的全程,Tirzepatide 在糖尿病发病全程中均显示出了降糖、降体重的显著获益,且低血糖事件发生率低。
In the SURPASS-AP-Combo trial, once-weekly tirzepatide was associated with improved glycemic control and weight loss versus insulin glargine and was generally well tolerated in an Asia-Pacific, predominately Chinese, population with type 2 diabetes (T2D). This post hoc subgroup analysis of ...